Reports Q3 revenue $44.44M, consensus $44.92M. “As announced on November 2, we are thrilled to welcome Chas McKhann as the new CEO of Silk Road Medical,” said Jack Lasersohn, Chairman of the Board of Directors. “Chas is a skilled and experienced leader with a track record of effectively building and scaling medical device businesses into underpenetrated markets. We believe he is the right leader to leverage our strong infrastructure, skilled commercial team, and substantial body of clinical evidence to drive further TCAR adoption.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SILK:
- Silk Road Medical Reports Third Quarter 2023 Financial Results
- Silk Road Medical names McKhann as CEO
- Silk Road Medical to Report Third Quarter 2023 Financial Results on November 8, 2023
- Silk Road Medical upgraded to Peer Perform from Underperform at Wolfe Research
- Silk Road Medical price target lowered to $8 from $28 at BofA